Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.89 - $9.56 $35,929 - $58,316
6,100 New
6,100 $44,000
Q4 2023

Feb 14, 2024

BUY
$2.93 - $7.32 $41,606 - $103,944
14,200 Added 1183.33%
15,400 $112,000
Q3 2023

Nov 14, 2023

SELL
$3.75 - $7.46 $49,500 - $98,472
-13,200 Reduced 91.67%
1,200 $4,000
Q2 2023

Aug 14, 2023

SELL
$5.32 - $6.79 $140,448 - $179,256
-26,400 Reduced 64.71%
14,400 $83,000
Q1 2023

May 15, 2023

SELL
$2.88 - $8.51 $54,432 - $160,839
-18,900 Reduced 31.66%
40,800 $265,000
Q4 2022

Feb 14, 2023

BUY
$2.09 - $3.39 $87,362 - $141,702
41,800 Added 233.52%
59,700 $164,000
Q3 2022

Nov 14, 2022

BUY
$2.17 - $4.3 $6,293 - $12,470
2,900 Added 19.33%
17,900 $52,000

Others Institutions Holding VRCA

About Verrica Pharmaceuticals Inc.


  • Ticker VRCA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,094,100
  • Market Cap $327M
  • Description
  • Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...
More about VRCA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.